By William Brown, Medical Cannabis Educator

Medical Cannabis is no longer fringe; it is a clinically supported, patient-driven tool for managing complex health conditions. Yet despite its growing legitimacy, education around its use remains fragmented, stigmatized, and underfunded. This article will show why prioritizing medical Cannabis is essential for public health. Highlighting why systemic barriers continue to suppress understanding, ultimately reinforcing stigma, not just around medical use, but Cannabis itself, while also supplying a few possible solutions.

Why Medical Cannabis Deserves Priority

Therapeutic Potential

Medical Cannabis offers promising relief for a range of conditions, such as chronic pain, epilepsy, multiple sclerosis, anxiety, and more. Cannabis works by influencing the body’s Endocannabinoid System (ECS) [1], which is responsible for regulating essential functions like pain, mood, appetite, learning, memory, and immune response, to name a few. For example, research [2] has shown that CBD can reduce seizure frequency in certain forms of epilepsy, such as Dravet syndrome. At the same time, THC may help alleviate neuropathic pain associated with multiple sclerosis. A 2017 study [3], published in the Journal of Pain, found that medical Cannabis significantly reduced chronic pain symptoms in patients who did not respond to standard therapies. These findings highlight that Cannabis can provide benefits where conventional treatments may be less effective, making it a valuable option for personalized medicine.

This 2024 systematic review [4] mapped 194 studies and found “positive” or “potentially positive” effects of medical Cannabis on pain, insomnia, seizures, anxiety, muscle spasticity, and more.

Cannabis as an Opioid-Sparing Therapy

In states with medical Cannabis programs, patients often substitute Cannabis for opioids to manage pain. This shift correlates with reduced opioid prescriptions and overdose mortality, positioning Cannabis as a key component in harm reduction strategies. A 2025 meta-analysis [5] reviewed randomized and observational studies, finding that Cannabis may reduce opioid use in chronic pain patients, though evidence certainty varies.

Clinical Outcomes in Opioid Use Disorder Patients

A 2025 observational study [6] found that medical Cannabis improved pain severity, sleep quality, and quality of life in patients with opioid use disorder. However, it did not significantly reduce illicit opioid use.

This 2025 report [7] compiles dozens of studies showing reduced opioid dependency and improved pain outcomes among patients using medical Cannabis.

Decades of prohibition and the “war on drugs” have shaped public perception, casting Cannabis as dangerous or illegitimate. This stigma continues to influence policy, media, and medical discourse, impeding educational progress even in legalized states.

Regulatory and Research Barriers with Possible Solutions

Despite growing evidence, medical Cannabis remains marginalized, not because of a lack of efficacy, but because of entrenched systems that resist change.

Governmental Resistance

Barrier: Federal illegality [8] restricts large-scale clinical trials and institutional endorsement. Without robust data, many medical institutions hesitate to integrate Cannabis into formal education or practice. These limitations perpetuate the myth that Cannabis lacks legitimacy, reinforcing public skepticism and professional hesitancy.

Possible Solutions:

• Deschedule Cannabis to allow federally funded research and standardized regulation

• Establish NIH/CDC-backed grants for Cannabis and ECS studies

• Create standard guidelines for medical Cannabis use to reduce confusion across states

Medical and Institutional Resistance

Barrier: Most medical schools do not teach the endocannabinoid system, leaving physicians underprepared. Without formal training, many providers are reluctant to recommend Cannabis, even when patients inquire. Inconsistent laws across states create confusion and discourage standardized education. In prohibition states, providers may lack access to training; in legal states, education remains optional and uneven. When providers lack training, patients face judgment or dismissal, fueling stigma and undermining trust in care.

Possible Solutions:

• Integrate ECS and Cannabis pharmacology into medical, nursing, and pharmacy curricula

• Offer more in-depth CME/CEU programs on Cannabis science for practicing clinicians

• Develop open-access toolkits with dosage guidance, case studies, and patient communication strategies

• Collaborate with Certified Cannabis Educators (they may not have a medical, nursing, or pharmacy degree, but the training is the same) who have been vetted based on the following:

  1. Training/certification, expertise in Cannabis science

  2. Personal and patient experience

  3. Knowledge of the endocannabinoid system

  4. A commitment to ethical standards such as transparency, patient confidentiality, and evidence-based education.

Corporate Influence and Pharmaceutical Competition

Barrier: Cannabis challenges the pharmaceutical model. It is individual, plant-based, and often unpatentable. This threatens entrenched interests and slows institutional support for research and education. Resistance from entrenched industries frames Cannabis as a threat rather than a therapeutic ally, stigmatizing both patients and providers who advocate for its use.

Possible Solutions:

• Incentivize public-private partnerships between Cannabis researchers/educators and healthcare institutions

• Require open-access publication of federal and publicly funded Cannabis research

• Strengthen patient advocacy coalitions to amplify voices and counterbalance corporate resistance

Final Thought

Medical Cannabis deserves more than reluctant tolerance and outdated stigmas. These barriers, from policy to education, don’t just delay progress… they actively reinforce stigma by keeping Cannabis marginalized in medicine and misunderstood in society. Cannabis deserves informed, compassionate integration. Prioritizing education for providers, policymakers, and the public is essential to ensure safe, equitable access for patients who need it most.

Cannabis works better with Education!

Share this article. Cite the research. Advocate for evidence-based reform. Destigmatization begins with education.

References

1. Grinspoon, Peter. “The Endocannabinoid System: Essential and Mysterious by Dr. Grinspoon.” The Endocannabinoid System: Essential and Mysterious by Dr. Grinspoon, 28 Dec. 2022, www.effectivenewsletter.com/blog/the-endocannabinoid-system-essential-and-musterious-dr-peter-grinspoon.

2. Rodin, D., Maizels, Y. & Koman, I. Medical Cannabis Library: development of a curated database for research articles on cannabis therapeutic activity. J Cannabis Res 7, 39 (2025). doi.org/10.1186/s42238-025-00295-7.

3. Hill, Kevin P., et al. “Original Research Open Access.” https://www.liebertpub.com, 1 May 2017, doi/pdf/10.1089/can.2017.0012.

4. Montagner P, de Salas Quiroga A, Ferreira AS, Duarte da Luz BM, Ruppelt BM, Schlechta Portella CF, Abdala CVM, Tabach R, Ghelman R, Blesching U, Perfeito JPS and Schveitzer MC (2024) Charting the therapeutic landscape: a comprehensive evidence map on medical cannabis for health outcomes. Front. Pharmacol. 15:1494492. doi: 10.3389/fphar.2024.1494492.

5. Noori A, Miroshnychenko A, Shergill Y, et alOpioid-sparing effects of medical cannabis or cannabinoids for chronic pain: a systematic review and meta-analysis of randomised and observational studiesBMJ Open 2021;11:e047717. doi: 10.1136/bmjopen-2020-047717

6. Lent, M.R., Keen, R., Ruiz, M. et al. Clinical and psychosocial changes in adults with opioid use disorder and chronic pain using medical cannabis: a brief report. J Cannabis Res 7, 36 (2025). doi.org/10.1186/s42238-025-00297-5

7. “CANORML.” www.Canorml.Org/, Mar. 2025, www.canorml.org/OpioidStudies2.pdf.

8. Cooper ZD, Abrams DI, Gust S, Salicrup A, Throckmorton DC. Challenges for Clinical Cannabis and Cannabinoid Research in the United States. J Natl Cancer Inst Monogr. 2021 Nov 28;2021(58):114-122. doi: 10.1093/jncimonographs/lgab009. PMID: 34850896; PMCID: PMC8783595.

About William Brown:

William owns and operates WbC Therapeutics, a company based on the therapeutic application of Cannabis as medicine. He is also a patient and authorized caregiver in his state. William is a certified Cannabis educator and coach.

Contact William at WbC Therapeutics through email at [email protected] and click below to learn more about his services.